C22.0 C22.1 C24.0 C78.7 K72.9 K70 K74 K83.0 K75.4 E83.1 E83.0
Conditions
Interventions
Group 1: Retrospective registry-based analysis of all adult patients listed for primary liver transplantation within the Eurotransplant network between 2007 and 2024, irrespective of underlying indica
Sponsors
Klinik für Viszeral-, Transplantations-, Thorax- und Gefäßchirurgie
Chirurgie Innsbruck
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: • Registration in the Eurotransplant liver waiting list registry within the observation period 01/2007–12/2024 • Available listing date and defined waitlist outcome (transplantation, death, or delisting) • Documented primary diagnosis allowing classification into oncologic or non-oncologic indication • Availability of MELD score (laboratory or exception MELD) at time of listing • Assignable Eurotransplant member country
Exclusion criteria
Exclusion criteria: • Age < 18 years at the time of listing • Listing for combined or multi-organ transplantation (e.g. liver-kidney, liver-heart) • Missing information on key time variables (listing date or event date) • Missing assignment of a waiting list event (transplant, death or delisting) • Unclear or unclassifiable primary diagnosis • Duplicate registrations of the same listing process • Listing outside the defined observation period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in waitlist mortality resulting from a modeled expansion of liver transplantation eligibility criteria to selected hepatic malignancies. Waitlist mortality will be calculated as deaths per 1,000 patient-years using competing-risk methodology (transplantation and delisting as competing events) and compared between the current allocation scenario and simulated expanded-criteria scenarios. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Change in median time to transplantation across MELD strata and diagnostic groups. 2. Probability of transplantation within defined time intervals using competing risk methodology (death or delisting as competing events). 3. Estimated transplant benefit for newly eligible oncologic patient groups compared with the remaining waitlist population. 4. Changes in organ availability and allocation dynamics (proportion transplanted, delisting due to clinical deterioration). 5. Regional differences within the Eurotransplant network regarding waitlist mortality, transplant probability, and minimally required post-transplant survival thresholds. 6. Sensitivity analyses to determine the minimal acceptable 5-year post-transplant survival at which no relevant disadvantage to the existing waitlist population occurs. | — |
Countries
Austria, Belgium, Croatia, Germany, Hungary, Luxembourg, Netherlands, Slovenia
Contacts
Public ContactRupert Oberhuber
Chirurgie Innsbruck
Outcome results
None listed